FXN and Friedreich ataxia: We found that a commercially available HDACI (BML-210), and derivatives we have synthesized (pimelic diphenylamides), relieve repression of the FXN gene in lymphoid cell lines derived from FRDA patients, in primary lymphocytes from donor FRDA patient blood, and in the brain and heart of a mouse model for FRDA [8], [9].